EVALUATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN QUINIDINE AND NIFEDIPINE

被引:19
作者
BOWLES, SK
REEVES, RA
CARDOZO, L
EDWARDS, DJ
机构
[1] WAYNE STATE UNIV,COLL PHARM & ALLIED HLTH,DETROIT,MI 48202
[2] SUNNYBROOK HLTH SCI CTR,DEPT PHARM,TORONTO,ON,CANADA
[3] DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT MED,DETROIT,MI
[4] SUNNYBROOK HLTH SCI CTR,DEPT MED,TORONTO,ON,CANADA
[5] UNIV TORONTO,FAC MED,TORONTO M5S 1A1,ONTARIO,CANADA
[6] WAYNE STATE UNIV,SCH MED,DETROIT,MI 48201
[7] UNIV TORONTO,FAC PHARM,TORONTO M5S 1A1,ONTARIO,CANADA
[8] DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT PHARM,DETROIT,MI
关键词
D O I
10.1002/j.1552-4604.1993.tb05614.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quinidine and nifedipine appear to be subject to metabolism by the some isozyme of cytochrome P-450. In addition, both drugs have been reported to alter the pharmacokinetics of other compounds. To investigate a potential interaction, 10 healthy subjects (five male, five female) received quinidine sulfate (200 mg orally), nifedipine (20 mg orally), or the combination of both drugs every 8 hours for 4 doses using a randomized, cross-over study design with a 2-week washout period between treatments. Drug concentration, heart rate, and mean arterial pressure were measured at frequent intervals after the final dose. Quinidine concentrations were unchanged by the co-administration of nifedipine. Nifedipine area under the curve (AUC0-8) increased 36.6% from 333 to 455 mug . hr/L (P <.05) after quinidine administration. Heart rate was significantly higher in the nifedipine-quinidine treatment at 0.5, 1.0, 1.5, and 2.0 hours when compared with either drug alone. The maximum increase in heart rate (17.9 beats/minute) occurred at 0.5 hours after nifedipine administration and was significantly correlated with serum concentrations at that time (r = .78). These results suggest that quinidine inhibits nifedipine metabolism, and this pharmacokinetic interaction results in enhanced pharmacologic response.
引用
收藏
页码:727 / 731
页数:5
相关论文
共 20 条
[1]   CHANGES IN ANTIPYRINE AND INDOCYANINE GREEN KINETICS DURING NIFEDIPINE, VERAPAMIL, AND DILTIAZEM THERAPY [J].
BAUER, LA ;
STENWALL, M ;
HORN, JR ;
DAVIS, R ;
OPHEIM, K ;
GREENE, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (02) :239-242
[2]   INFLUENCE OF THE MENSTRUAL-CYCLE ON THEOPHYLLINE PHARMACOKINETICS IN ASTHMATICS [J].
BRUGUEROLLE, B ;
TOUMI, M ;
FARAJ, F ;
VERVLOET, D ;
RAZZOUK, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (01) :59-61
[3]   THE EFFECT OF COADMINISTRATION OF VERAPAMIL ON THE PHARMACOKINETICS AND METABOLISM OF QUINIDINE [J].
EDWARDS, DJ ;
LAVOIE, R ;
BECKMAN, H ;
BLEVINS, R ;
RUBENFIRE, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (01) :68-73
[4]   NIFEDIPINE-INDUCED ALTERATIONS IN SERUM QUINIDINE CONCENTRATIONS [J].
FARRINGER, JA ;
GREEN, JA ;
OROURKE, RA ;
LINN, WA ;
CLEMENTI, WA .
AMERICAN HEART JOURNAL, 1984, 108 (06) :1570-1572
[5]  
GREEN JA, 1983, CLIN PHARMACY, V2, P461
[6]  
GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287
[7]   QUINIDINE - POTENT INHIBITION OF SPARTEINE AND DEBRISOQUINE OXIDATION INVIVO [J].
INABA, T ;
TYNDALE, RE ;
MAHON, WA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (02) :199-200
[8]   NIFEDIPINE - KINETICS AND DYNAMICS IN HEALTHY-SUBJECTS [J].
KLEINBLOESEM, CH ;
VANBRUMMELEN, P ;
VANDELINDE, JA ;
VOOGD, PJ ;
BREIMER, DD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) :742-749
[9]   SINGLE-DOSE QUINIDINE TREATMENT INHIBITS METOPROLOL OXIDATION IN EXTENSIVE METABOLIZERS [J].
LEEMANN, T ;
DAYER, P ;
MEYER, UA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 29 (06) :739-741
[10]   ELUCIDATION OF THE NIFEDIPINE-QUINIDINE INTERACTION [J].
MUNGER, MA ;
JARVIS, RC ;
NAIR, R ;
KASMER, RJ ;
NARA, AR ;
URBANCIC, A ;
GREEN, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :411-416